Syntonix discovers and develops novel, long-acting, proprietary therapeutic products using the company’s proprietary Fc-fusion proteins and other engineered ligands which bind to specific Fc receptors. These technologies, including Syntonix’ drug delivery platform technology Transceptor™, harness the body’s natural pathways for protecting antibodies against premature destruction and for transporting antibodies across cell barriers such as those in the lungs and intestines. Syntonix focuses on using these technologies to create next generation treatments for devastating chronic diseases such as hemophilia, anemia, and autoimmune disorders. Syntonix develops selected products for specialty indications, such as hemophilia, on its own. Other products will be evaluated and commercialized through partnerships with companies with established market positions. The company is headed by an experienced management team and has focused initially on using its proprietary technology to enhance existing drugs with proven safety, efficacy, and economic return. Syntonix currently occupies a 25,000 square foot state-of-the-art laboratory facility, including a cGMP clinical manufacturing suite, in Waltham, Massachusetts.